Skip to main content
letter
. 2022 Sep 9;11:53. doi: 10.1186/s40164-022-00307-9

Table 1.

Immunosuppressed patients with COVID-19 completing treatment without relapse of the viral infection

Factors Patient identification
1 2 3 4 5 6 7 8 9 10
Age (years) 51 74 49 94 51 66 72 57 51 84
Sex (male/female) M M F F F F M M M M
Primary disease Follicular lymphoma Follicular lymphoma Myasthenia gravis

Myasthenia gravis

Rheumatoid arthritis

Kidney transplant Kidney transplant Kidney transplant Liver transplant Chronic myeloid leukemia Chronic lymphocytic leukemia
Other comorbidity None Hypertension Thyrotoxicosis Hypertension Epilepsy Hypertension

Hypertension

Diabetes mellitus

Hypertension

Diabetes mellitus

Nephrotic syndrome

None

Diabetes mellitus

Coronary heart disease

COVID-19 vaccination Yes Yes No Yes No Yes Yes Yes No Yes
Anti-CD20 antibody Obinutuzumab

Rituximab

Obinutuzumab

None None None None None None None None
Immunosuppressive agents for primary disease

Cyclophosphamide

Prednisolone

Cyclophosphamide

Prednisolone

Tacrolimus

Tacrolimus

Prednisolone

Tacrolimus

Mycophenolate mofetil

Everolimus

Prednisolone

Tacrolimus

Mycophenolate mofetil

Methylprednisolone

Tacrolimus

Mycophenolate mofetil

Methylprednisolone

Tacrolimus

Mycophenolate mofetil

Everolimus

Iguratimod

Tocilizumab

Prednisolone

Prednisolone

Initial antiviral therapy

Switched antiviral therapy

Remdesivir

Remdesivir

Nirmatrelvir/Ritonavir

Remdesivir

Nirmatrelvir/Ritonavir

Remdesivir

Molnupiravir

Remdesivir

Remdesivir

Nirmatrelvir/Ritonavir

Remdesivir

Remdesivir

Nirmatrelvir/Ritonavir

Remdesivir Remdesivir
Neutralizing antibody-based therapy

Sotrovimab

Casirivimab/Imdevimab

Sotrovimab Casirivimab/Imdevimab Casirivimab/Imdevimab Sotrovimab Sotrovimab Sotrovimab Sotrovimab Casirivimab/Imdevimab Sotrovimab
Initial Ct value 18.6 19.8 25.3 18.2 19.6 25 17.9 22.4 15 25.6
Initial spike-specific antibody Negative Negative 163 U/mL Negative Negative Negative Negative Negative Negative 1.41 U/mL
Length of antiviral and antibody-based therapy 10 days 14 days 9 days 10 days 10 days 21 days 20 days 18 days 8 days 7 days
Length of hospital stay 14 days 19 days 13 days 28 days 13 days 23 days 43 days 18 days 12 days 17 days